Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
⭐️ACR20, 50,70 response
⭐️significant resolution of enthesitis/dactylitis
Abs#OP0228
#EULAR2021 @RheumNow
Links:
04-06-2021
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.